Citations

Clear

11 citation(s) found for "Lassen, Yasmin".

Selection of the Most Appropriate Radiation Treatment Modality for Children's Cancers: A Paediatric Radiation Oncology Society (PROS) Position Paper on the Ethical Utilization of Proton Therapy
Indelicato, Daniel J. , Mahajan, Anita , Parkes, Jeannette , Paulino, Arnold C. , Beljoudi, Guillaume, Kristensen, Ingrid, Lassen, Yasmin, Njiraini, Pauline Njoki , Qureshi, Bilal Mazhar , Robles, Beatriz Garcia, Seiersen, Klaus , Esiashvili, Natia , Indelicato, Daniel J , Parkes, Jeannette , Paulino, Arnold C , Njiraini, Pauline Njoki , Qureshi, Bilal Mazhar , Gaze, Mark N , Laprie, Anne , Robles, Beatriz Garcia, Timmermann, Beate , Gaze, Mark N.

Mayo Clinic

Pediatric Blood & Cancer | November 20, 2025 | Volume: 73 | Issue: 2 | Pages: No page available

10.1002/pbc.32155 | PMID 41261937 Get It

ABSTRACT Background Proton beam therapy (PBT) offers dosimetric advantages in pediatric radiotherapy by reducing radiation exposure to healthy tissues. However, broad implementation raises important ethical, logistical, and equity considerations, especially in settings with limited access to advanced technologies. Procedure This position paper by the Paediatric Radiation Oncology Society (PROS) reviews the clinical rationale for selecting radiotherapy modalities in children, with a specific focus on ethical utilization of PBT. The document synthesizes evidence on the benefits and limitations of modern photon and proton therapies, explores disparities in access, outlines the role of local pediatric radiation oncologists, and addresses the impact of industry‐driven messaging on family decision‐making. Results While PBT offers clinical benefit in selecting pediatric cancers, high‐quality photon‐based treatments such as IMRT and VMAT remain effective and widely accessible alternatives. The referral and evaluation process for PBT is complex and may introduce treatment delays. Travel and financial burdens can exacerbate disparities. PROS underscores the critical role of local pediatric radiation oncologists in counseling families, and calls for balanced, evidence‐based communication from providers and industry stakeholders. Conclusions PROS advocates for an ethical, equitable, and evidence‐informed approach to radiotherapy modality selection in children, reflecting holistic considerations beyond dosimetry. Proton therapy should be pursued when clinically indicated and accessible without compromising timely care. Investment in a comprehensive radiation therapy infrastructure, including professional education, collaborative research, and responsible public messaging, is essential to optimize pediatric cancer outcomes globally.
Selection of the Most Appropriate Radiation Treatment Modality for Children’s Cancers: A Paediatric Radiation Oncology Society (PROS) Position Paper on the Ethical Utilization of Proton Therapy
Indelicato, Daniel J. , Mahajan, Anita , Parkes, Jeannette , Paulino, Arnold C. , Beldjoudi, Guillaume , Kristensen, Ingrid, Lassen–Ramshad, Yasmin , Njiraini, Pauline Njoki , Robles, Beatriz García, Seiersen, Klaus , Paulino, Arnold C , Parkes, Jeannette , Indelicato, Daniel J , Njiraini, Pauline Njoki , Esiashvili, Natia , Beljoudi, Guillaume, Laprie, Anne , Lassen, Yasmin, Qureshi, Bilal Mazhar , Robles, Beatriz Garcia, Timmermann, Beate , Gaze, Mark N.

Mayo Clinic

No container title available | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.175992134.44586481/v1 Get It

Twenty Years of the Paediatric Radiation Oncology Society
Gaze, Mark N. , Beldjoudi, Guillaume , Freeman, Carolyn, Indelicato, Daniel J. , Kortmann, Rolf‐Dieter , Lassen, Yasmin, Mahajan, Anita , Marcus, Karen J. , Njiraini, Pauline Njoki , Parkes, Jeannette , Qureshi, Bilal Mazhar , Robles, Beatriz García, Seiersen, Klaus , Indelicato, Daniel J , Njiraini, Pauline Njoki , Parkes, Jeannette , Paulino, Arnold C , Qureshi, Bilal Mazhar , Gaze, Mark N , Carrié, C. , Kristensen, Ingrid Fagerström , Laprie, Anne , Paulino, Arnold C. , Robles, Beatriz García, Timmermann, Beate , Esiashvili, Natia

Mayo Clinic

Pediatric Blood & Cancer | May 5, 2025 | Volume: 72 | Issue: 7 | Pages: No page available

10.1002/pbc.31764 | PMID 40320663 Get It

ABSTRACT In 2005, the Paediatric Radiation Oncology Society (PROS), a multi‐professional association to promote radiotherapy for children and young people, was created. Its mission has been to educate those involved in this field, and to improve the standards of radiation oncology care for children, adolescents, and young adults across the globe, not least in less privileged settings where the majority of the world's children, and most with cancer, live. Through regular congresses, and joint meetings with the International Society of Paediatric Oncology (SIOP), PROS has facilitated a focus on this treatment modality, and advocated on behalf of those who might benefit from it.
Influence of radiotherapy technique on incidental dose to the whole ventricular system in focal irradiation of nongerminomatous germcell tumours
Lassen–Ramshad, Yasmin , Seiersen, Klaus , Gleeson, Ian , Mahajan, Anita , Sehested, Astrid , Toussaint, Laura , Joergensen, Morten, Agerbæk, Mads , Paulino, Arnold C. , Paulino, Arnold C , Safwat, Akmal , Joergensen, Morten, Ajithkumar, Thankamma

Mayo Clinic

Acta Oncologica | May 12, 2023 | Volume: 62 | Issue: 5 | Pages: 503-507

10.1080/0284186x.2023.2211713 | PMID 37171106 Get It

Reply to “Proper tumor classification and growth rate are key elements when considering indications and results of radiotherapy for head and neck paragangliomas”
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette

Mayo Clinic

Head & Neck | May 6, 2019 | Volume: 41 | Issue: 8 | Pages: 2837-2838

10.1002/hed.25800 | PMID 31058391 Get It

Efficacy of proton therapy in children with high‐risk and locally recurrent neuroblastoma
Bagley, Alexander F. , Grosshans, David R. , Philip, Nancy V., McAleer, Mary Frances , McGovern, Susan L. , Lassen–Ramshad, Yasmin , Mahajan, Anita , Paulino, Arnold C. , Foster, Jennifer , Paulino, Arnold C , Bagley, Alexander F

Mayo Clinic

Pediatric Blood & Cancer | May 3, 2019 | Volume: 66 | Issue: 8 | Pages: No page available

10.1002/pbc.27786 | PMID 31050179 Get It

Abstract Purpose Proton therapy is currently used in the management of pediatric tumors to decrease late toxicities. However, one of the criticisms of proton therapy is the limited data regarding efficacy on disease control. The purpose of this study was to examine local and distant control rates after proton therapy for neuroblastoma. Methods and materials Eighteen patients with high‐risk ( n = 16) and locally recurrent neuroblastoma ( n = 2) were treated with curative intent and received proton therapy to the primary site and up to three post‐induction MIBG‐avid metastatic sites. Primary sites ( n = 18) were treated to 21–36 Gy (relative biological effectiveness [RBE]), and metastatic sites ( n = 16) were treated to 21–24 Gy (RBE). Local control and survival rates were calculated using the Kaplan–Meier method. Results With a median follow‐up of 60.2 months, two‐ and five‐year local control rates at the irradiated primary site were 94% and 87%, respectively. No failures at irradiated distant metastatic sites were observed. The five‐year progression‐free survival (PFS) was 64%, and the five‐year overall survival (OS) was 94%. The extent of surgical resection was not associated with local control, PFS, or OS. No radiation‐related nephropathy or hepatopathy was reported. Conclusions Excellent local control was achieved using proton therapy to the primary and post‐induction MIBG‐positive distant sites. The predominant site of failure is progression in post‐induction non‐MIBG‐avid distant sites. Although proton therapy provides high rates of local control with acceptable toxicity for neuroblastoma, further advances in systemic therapy are needed for the improved control of systemic disease.
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy
Ludmir, Ethan B. , Mahajan, Anita , Jones, Jeremy , Ketonen, Leena , Su, Jack , Grosshans, David R. , McAleer, Mary Frances, McGovern, Susan L. , Lassen–Ramshad, Yasmin , Adesina, Adekunle M. , Dauser, Robert C., Weinberg, Jeffrey S. , Chintagumpala, Murali , Ludmir, Ethan B , Paulino, Arnold C. , McAleer, Mary Frances

Mayo Clinic

Neuro-Oncology | February 6, 2019 | Volume: 21 | Issue: 5 | Pages: 686-695

10.1093/neuonc/noz042 | PMID 30753704 Get It

Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette

Mayo Clinic

Head & Neck | January 11, 2019 | Volume: 41 | Issue: 6 | Pages: 1770-1776

10.1002/hed.25611 | PMID 30633446 Get It

Abstract Background Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network. Methods Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed. Results The median follow‐up was 48 months (1‐456). Sixty‐two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow‐up longer than 20 years experienced disease progression. Conclusion RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long‐term follow‐up is required.
RONC-11. EVALUATION OF DIFFERENT RADIOTHERAPY TECHNIQUES ON INCIDENTAL RADIATION DOSES TO THE WHOLE VENTRICULAR SYSTEM DURING FOCAL IRRADIATION FOR NON GERMINOMATOUS GERM CELL TUMOURS AFTER CHEMOTHERAPY
Lassen–Ramshad, Yasmin , Seiersen, Klaus , Gleeson, Ian , Mahajan, Anita , Paulino, Arnold C. , Ajithkumar, Thankamma

Mayo Clinic

Neuro-Oncology | June 21, 2018 | Volume: 20 | Issue: suppl_2 | Pages: i176-i177

10.1093/neuonc/noy059.673 Get It

The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette

Mayo Clinic

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94

10.4081/rt.2014.5465 | PMID 25276326 Get It

The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.